Verismo Therapeutics
Philadelphia, PA
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer.
verismotherapeutics.comCompany Details
Founded
- 2020
Employees
- Between 20 - 50 employees
Raised
- $44,200,000
Headquarters Location
- Philadelphia, PA
Public
- No
Acquired
- Yes
CEO
Bryan Kim
Founders
- Donald SiegelBryan KimMichael Milone
Company Collections
These are collections Verismo Therapeutics is a part of. Click on the collection name to view similar companies.
Verismo Therapeutics' Industries
Verismo Therapeutics Headquarters Location
Total Amount Raised: $44,200,000
Verismo Therapeutics Funding Rounds
Seed
$4,050,000
Seed Investors
Institute for Follicular Lymphoma InnovationGrant
$150,000
Grant Investors
ScaleReadySeed
$17,000,000
Seed Investors
DongKoo Bio & Pharma Co.Hong Leong BankSeed
$7,000,000
Seed Investors
BRV Capital ManagementSeed
$16,000,000
Verismo Therapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Verismo Therapeutics.